Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04591002 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary completion date: Nov 20, 2025 to Sep 1, 2027
Start date: Jul 26, 2022 to Sep 11, 2022
Study completion date: Oct 30, 2028 to Dec 1, 2027
v7
NotableTrial status: Withdrawn to Recruitingv6Show 5 more changesShow less
Primary completion date: Oct 7, 2020 to Nov 20, 2025
Start date: Oct 7, 2020 to Jul 26, 2022
Enrollment target: 0 to 43
Study sites: 1 to 2
Study completion date: Oct 30, 2020 to Oct 30, 2028
MinorRe-verified, no change to tracked fieldsv5
NotableTrial status: Suspended to Withdrawnv4Show 4 more changesShow less
Enrollment target: estimated 56 to confirmed 0
Primary completion date changed from estimate of Nov 18, 2022 to Oct 7, 2020
Study completion date changed from estimate of Nov 18, 2022 to Oct 30, 2020
Start date changed from estimate of Nov 18, 2022 to Oct 7, 2020
StoppedTrial status: Not Yet Recruiting to SuspendedSponsor's reason: Further consultation is required, we plan to submit it again as a new project and proceed.
Primary completion date: Oct 30, 2021 to Nov 18, 2022
Start date: Jan 31, 2021 to Nov 18, 2022
Study completion date: Oct 30, 2022 to Nov 18, 2022
v3
NotableStart date: Oct 30, 2020 to Jan 31, 2021v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study designed to assess the efficacy of osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection for actionable EGFR mutation-positive stage I lung adenocarcinoma.